González EIR, Castro PA, Sánchez SS, Camarín SEI, Hernández ZMF, Juárez SG, Chiquillo DM, Yarce CLM

Language: Spanish
References: 2
Page: 397-400
PDF size: 223.93 Kb.

ABSTRACT

Introduction: genomic characterization is vital for the treatment and prognosis of non-small cell lung cancer (NSCLC) but can be challenging to interpret. Case presentation: a 62-year-old man with NSCLC adenocarcinoma had EGFR L861Q mutation, EGFR amplification, and MET amplification. Initial treatment with osimertinib resulted in mixed responses, with overall reduction but new hepatic lesions with PIK3CA and BRAF mutations. After CNS metastasis, the new profile again found mutations in EGFR and MET. Conclusions: genomic characterization is crucial for guiding treatment. New therapies promote tumor heterogeneity, so a multidisciplinary approach is necessary.

REFERENCES

1. Yang SR, Schultheis AM, Yu H, Mandelker D, Ladanyi M, Büttner R. Precision medicine in non-small cell lung cancer: current applications and future directions. Semin Cancer Biol. 2022; 84: 184-198.

2. Mu Y, Hao X, Xing P, Hu X, Wang Y, Li T et al. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. J Cancer Res Clin Oncol. 2020; 146 (9): 2427-2433.